Methylene Blue: Evidence, Safety, Dosing, and Access

Methylene blue, also called methylthioninium chloride, is a small molecule used in specific medical and procedure settings and studied in many human trials. FDA-approved labeling exists for a prescription methylene blue product, but the research uses discussed on this page should not be assumed to be FDA-approved uses 13. Its evidence grade is A because PubMed indexes multiple randomized controlled trials, but that grade measures study quantity and design—not whether it works for every use or is safe for daily self-use 1 2.

What it is

Methylene blue is a small molecule and redox dye, meaning it can move electrons in chemical reactions 14. It is also called methylthioninium chloride, and Provayblue is one name patients may see in medical discussions.

In the retrieved human literature, methylene blue appears in several very different settings: septic shock trials, brain-imaging research, residual symptoms of bipolar disorder, colonoscopy screening, surgical staining, nerve-block research, catheter-lock discussion, and antimicrobial photodynamic therapy 1 3 8 10 11 12. That range is one reason online claims can get confusing: a study in one medical setting does not prove value in another.

Names: methylene blue, methylthioninium chloride, and Provayblue

• Methylene blue: the common name used in most patient searches and many study titles.
• Methylthioninium chloride: a chemical name used in some medical and pharmacy contexts.
• Provayblue: a brand name patients may encounter when reading about this substance.
• Redox dye: a plain-language way to describe its electron-transfer chemistry.

At Chia, we write about compounds like this because patients often meet them through wellness claims before they see the medical evidence. For broader context on how to read aging and metabolic claims, our guides to longevity labs, NMN, and healthy aging for seniors may help.

Mechanism of action

Methylene blue is discussed in three main mechanism lanes: redox biology, nitric oxide signaling, and dye or light-activated procedural use 1 2 14. The key point is that mechanism does not equal clinical benefit; each claim still needs human outcome data in the same setting.

Redox biology and mitochondrial research: what can and cannot be claimed

Methylene blue is often described online as a mitochondrial compound because redox chemistry can affect electron flow 14. The retrieved human records support that it has been studied in the human brain and in clinical settings, but they do not prove longer life, weight loss, or broad metabolic optimization 8.

A randomized human brain-imaging study reported that methylene blue modulated functional connectivity in the human brain 8. That is a neuroscience finding, not proof that daily use improves memory, focus, or longevity.

Nitric oxide signaling and shock research

In septic shock research, methylene blue has been studied as an adjunctive intervention in seriously ill patients, with discussion of nitric oxide pathway effects in this acute-care context 1 2 14. Another randomized trial focused on sublingual microcirculation in septic shock, which is blood flow in small vessels under the tongue used as a window into microvascular function 9.

These studies belong to acute-care medicine. They do not support taking methylene blue for routine wellness, weight management, or general energy use.

Dye, imaging, and photodynamic uses in clinical studies

Methylene blue is also studied because it has visible dye properties and can be paired with light in antimicrobial photodynamic therapy. Human studies in the retrieved set include parotid surgery staining, thyroid and parathyroid surgery imaging, colonoscopy screening, and herpes simplex photodynamic therapy 3 5 6 11.

Evidence

Methylene blue receives evidence grade A under the assigned rubric because multiple human randomized controlled trials are indexed for the compound 1 2 8 10. That grade describes the amount and design of research, not a guarantee that it helps a specific person or goal.

Evidence grade rubric

A — two or more human randomised controlled trials. B — one human randomised trial, or two or more human clinical trials. C — human research exists, none of it randomised. D — animal or in-vitro research only; no human studies indexed. E — no trial evidence indexed in PubMed. The grade describes the quantity and design of published evidence, not whether the substance works, and not whether it is safe.

Why an A grade does not mean proven benefit or safety for every use

The retrieved evidence is broad, not uniform. A septic shock trial, a bipolar disorder crossover study, and a colonoscopy screening study ask different questions, use different endpoints, and involve different types of patients 1 10 11.

That matters for metabolic health readers. The retrieved methylene blue studies do not establish it as a treatment for weight loss, insulin resistance, healthy aging, or mitochondrial “optimization.” For metabolic-health topics with stronger direct relevance, we explain evidence standards in our articles on metformin and healthy aging habits.

What has methylene blue been studied for in humans?

What studies exist

This table is retrieved from PubMed and ClinicalTrials.gov rather than assembled by hand, so it shows what is indexed — including the absences. Last retrieved 2026-09-08.

Reported dosing ranges

Methylene blue dosing depends heavily on route and setting. The retrieved records supplied for this page identify study topics and populations, but they do not provide enough extractable numeric dose details in the available citation data to turn into patient-use guidance.

Because the supplied evidence does not give extractable numeric ranges here, we do not publish a dose chart that could be mistaken for instructions. This is especially important because the same substance can be studied by infusion, oral formulation, topical or procedural use, and light-based therapy in very different settings 2 3 11.

Legal status

This section is generated from a dated log of federal actions rather than written by hand, and it is re-checked daily against the Federal Register and FDA sources. Last checked 2026-09-08. See the full legal-status tracker for every compound we follow.

Safety

Methylene blue safety cannot be judged from an evidence grade alone. The retrieved trials cover specific medical settings, so they should not be stretched into a safety guarantee for daily or wellness use 1 8 10.

Why daily or wellness use needs clinician review

The strongest retrieved human studies are not daily wellness studies. They include septic shock, brain imaging, psychiatric symptoms, procedure visualization, surgery, and photodynamic therapy 1 3 8 10 11.

This is why our clinical lens is cautious: a compound can be well studied in hospitals or procedures and still be poorly studied for routine self-use. Individual risks can also change with other medicines, pregnancy status, enzyme deficiencies such as G6PD deficiency, and the reason someone wants to use it 13.

Adverse-event limits in the retrieved evidence

The supplied PubMed records do not provide a complete adverse-event table across all methylene blue uses. That does not mean adverse effects are absent; it means this page should not make broad reassurance claims from incomplete safety detail.

For patients, the practical safety issue is supply and supervision. A clinician-supervised process can review identity, dose form, route, medication interactions, and follow-up; “research use only” material from a marketplace is not medical care and is not designed around patient-specific monitoring.

Interactions

Methylene blue interactions are one of the main reasons it should be reviewed by a licensed clinician before use. The retrieved study set is not a full interaction database, so absence of an interaction trial in this list is not proof of safety.

Serotonergic medications and serotonin-toxicity concern

Patients often ask about serotonergic medications because serotonin toxicity is a serious clinical concern discussed in medical labeling and medication review contexts 13. If someone takes antidepressants, migraine medicines, stimulants, certain pain medicines, or multiple mood-related drugs, that history should be reviewed before any methylene blue decision.

G6PD deficiency, pregnancy, severe illness, and procedure-related use

G6PD deficiency, pregnancy, severe illness, and procedure-related use are not small details; they can change whether a clinician considers a medicine or procedure appropriate 13. The retrieved trials include seriously ill septic shock patients and procedure-based uses, which are not the same as a healthy adult using a wellness product 1 5 11.

If methylene blue is being considered around a procedure, the care team should know the full medication list, allergies, medical history, and pregnancy status. This is part of basic clinical review, not a formality.

How to obtain it legally

Methylene blue access should start with a medical question, not a shopping search. A safer process means a licensed clinician reviews why it is being considered, current diagnoses, medication list, pregnancy status when relevant, allergies, and risk factors before deciding whether any prescription or procedure-related use is appropriate.

Clinician evaluation, prescription decision, and licensed pharmacy process

A medical process usually has three parts: evaluation, a prescription decision when appropriate, and dispensing through a licensed pharmacy. A prescription is never automatic; it depends on the clinician’s judgment and the patient’s risk profile.

At Chia, this is how we think about medical access in general: the key safety divide is licensed care versus unlicensed supply. For treatments we do offer, patients complete an online health questionnaire, a licensed US provider reviews it, and medications are compounded by state-licensed 503A pharmacies and shipped when clinically appropriate. Compounded medications are not FDA-approved.

Why research-chemical vendors are not medical care

Research-chemical or marketplace products do not replace clinician review. They may leave patients without clear oversight for identity, impurity, sterility, route, interactions, adverse effects, or follow-up.

For longevity and metabolic-health decisions, it is better to separate curiosity from care. Reading about a compound is useful; starting one without medical review is a different step. Our guides to longevity labs and healthy aging for seniors explain lower-risk ways to think about goals before adding substances.

Chia note: education-only for this compound

Chia does not offer methylene blue. This page is education-only, written from our perspective as clinicians who help patients sort evidence, safety, and access questions before they act.

If your real goal is weight management, metabolic health, energy, or healthy aging, the next step may not be methylene blue at all. It may be reviewing labs, medications, sleep, nutrition, or evidence-based options with a clinician.

FAQ

Keep reading

Weight Management

Dulaglutide: Evidence, Safety, Dosing, and How It Compares

Weight Management

Metformin: Evidence, Safety, Dosing, and Access

Weight Management

Retatrutide: Evidence, Safety, Dosing Studied, and Access Questions